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Abstract 
Background: The Hedgehog (Hh) signaling pathway is vital to animal development as it
mediates the differentiation of multiple cell types during embryogenesis. In adults, Hh signaling
can be activated to facilitate tissue maintenance and repair. Moreover, stimulation of the Hh
pathway has shown therapeutic efficacy in models of Parkinson’s disease and diabetic
neuropathy. The underlying mechanisms of Hh signal transduction remain obscure, however:
little is known about the communication between the pathway suppressor Patched (Ptc), a
multipass transmembrane protein that directly binds Hh, and the pathway activator
Smoothened (Smo), a protein that is related to G-protein-coupled receptors and is capable of
constitutive activation in the absence of Ptc. 
Results: We have identified and characterized a synthetic non-peptidyl small molecule,
Hh-Ag, that acts as an agonist of the Hh pathway. This Hh agonist promotes cell-type-specific
proliferation and concentration-dependent differentiation in vitro, while  in utero it rescues
aspects of the Hh-signaling defect in Sonic hedgehog-null, but not Smo-null, mouse embryos.
Biochemical studies with Hh-Ag, the Hh-signaling antagonist cyclopamine, and a novel Hh-
signaling inhibitor Cur61414, reveal that the action of all these compounds is independent of
Hh-protein ligand and of the Hh receptor Ptc, as each binds directly to Smo. 
Conclusions: Smo can have its activity modulated directly by synthetic small molecules.
These studies raise the possibility that Hh signaling may be regulated by endogenous small
molecules in vivo and provide potent compounds with which to test the therapeutic value
of activating the Hh-signaling pathway in the treatment of traumatic and chronic
degenerative conditions.
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The  hedgehog  (hh) gene was identified two decades ago in
Drosophila as a critical regulator of cell-fate determination
during embryogenesis [1]. Subsequent work in several model
systems has defined and characterized the Hh gene family
that encodes highly conserved secreted signaling proteins (for
review see [2]). Hedgehog (Hh) proteins are synthesized as
approximately 45 kDa precursors that autoprocess in an
unprecedented fashion, resulting in the covalent attachment
of a cholesterol moiety to the amino-terminal half of the
precursor [2]. This processed amino-terminal domain,
Hh-Np, is responsible for the activation of a unique and
complex signaling cascade that is essential for controlling
cell fate throughout development and into adulthood [2].
In mammals there are three Hh-family proteins: Sonic
(Shh), Indian (Ihh), and Desert (Dhh). Gene-targeting
experiments in mice have demonstrated that the develop-
ment and patterning of essentially every major organ
requires input from the Hh pathway [2].
In vitro culture systems of neuronal tissues have been used
to characterize the biology of the Hh-signaling pathway.
Most notably, the neural-plate explant assay has defined
the concentration-dependent role that ventrally expressed
Shh plays in opposing dorsally expressed bone morpho-
genetic proteins (BMPs) to pattern the neural tube [2]. The
assay demonstrates that the Hh-signaling cascade can dis-
tinguish between small concentration differences in the Hh
ligand to instruct the differentiation of specific neuronal
cell types. Additional insights have been gained by utilizing
cultures of postnatal cerebellar neuron precursors [2].
These studies have shown that Hh patterns the cerebellum
by promoting proliferation of the granule neuron precur-
sors. Given the role that Hh signaling plays in promoting
progenitor-cell proliferation, it is not surprising that mis-
regulation of Hh signaling has been implicated in the
biology of certain cancers, in particular basal cell carci-
noma (BCC) and medulloblastoma.
The Hh-signaling pathway comprises three main compo-
nents: the Hh ligand; a transmembrane receptor circuit
composed of the negative regulator Patched (Ptc) plus an
activator, Smoothened (Smo); and finally a cytoplasmic
complex that regulates the Cubitus interruptus (Ci) or Gli
family of transcriptional effectors. Additional pathway com-
ponents are thought to modulate the activity or subcellular
distribution of these molecules [2]. There is positive and
negative feedback at the transcriptional level as the Gli1 and
Ptc1 genes are direct transcriptional targets of activation of
the pathway. 
Smo is a seven-pass transmembrane protein with homology
to G-protein-coupled receptors (GPCRs), while Ptc is a
twelve-pass transmembrane protein that resembles a
channel or transporter. Consistent with its role as an essen-
tial pathway inhibitor, removal of Ptc renders the Hh
pathway constitutively ‘on’, independent of the Hh ligand.
Similarly, specific point mutations in the transmembrane
helices of Smo are capable of constitutively stimulating the
pathway, effectively bypassing Ptc inhibition [3]. At present,
a controversy surrounds the mechanism by which Ptc
inhibits Smo. Although early studies suggested a simple,
direct, stoichiometric regulation, more recent data support a
more complicated indirect or catalytic model [2]. And
although it has been demonstrated that Hh directly interacts
with [4] and destabilizes [5] Ptc, the downstream molecular
events remain obscure. In particular, little is known about
the means by which Ptc exerts its inhibitory effect on Smo,
or how Smo communicates with the cytoplasmic Ci/Gli
transcription factor complex. 
Through a ‘chemical genetic’ approach of identifying and
studying the mechanism of action of small-molecule ago-
nists (and antagonists), we hoped to uncover some of the
complexities of the Hh-signaling system. Small-molecule
modulators of growth-factor pathways have proven valuable
in providing enhanced understanding of the intracellular
events that occur subsequent to receptor activation, and in
establishing the biological functions of these pathways
[6-8]. In Hh signaling, multiple insights have been gained
through the use of the plant-derived Hh antagonist
cyclopamine [9-16] and a recently identified synthetic
small-molecule Hh-signaling inhibitor, Cur61414 [17].
Interestingly, these specific inhibitors of Hh signaling
appear to function downstream of Ptc but their precise mol-
ecular target(s) and mechanism of action are unknown. 
Although genetic manipulations involving gain-of-function
point mutations of Smo [3] have demonstrated that the
pathway can be activated independently of Hh ligand, no
small molecules with this capability have been identified.
Indeed, it has proven difficult to identify small-molecule
agonists of any signaling pathway activated by a protein
ligand. Two examples have recently been described,
however. One involved identification of a non-peptide acti-
vator of the granulocyte colony-stimulating factor (GCSF)
pathway that appeared to act via receptor oligomerization
[18]. Another report described a small-molecule activator of
the insulin-signaling pathway that also acts at the level of
the receptor [19].
Since the Hh receptor, Ptc, serves to inhibit signaling, a
small-molecule pathway activator would need to be capable
of one of the following: first, interfering with the inhibitory
effect that Ptc exerts on Smo; second, activating Smo without
affecting Ptc; or third, activating the pathway downstream of
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would provide useful information concerning the details of
Hh signaling and would also provide a simple means of
modulating activity of the pathway in vivo or in vitro.
In this article, we show that a non-peptidyl small-mole-
cule agonist of Hh signaling has been identified that has
all the known signaling properties of the recombinant Hh
protein. But this agonist, unlike Hh protein, appears to
bypass the Ptc-regulatory step, by interacting directly with
Smo. Furthermore, studies with the agonist and several
antagonists of Hh signaling suggest that Smo can be acti-
vated or inhibited by direct interaction with small-
molecule ligands. These observations suggest that the
Ptc-Smo receptor circuit may incorporate native small-
molecule ligands in the regulation of Hh signaling.
Results
Isolation of Hh agonists by high-throughput
screening
To identify small-molecule agonists of Hh signaling, we
established a mammalian-cell-based assay. After testing
several cell lines for Hh-dependent induction of the target
genes Ptc1 and Gli1 [2], we identified C3H10T1/2 and TM3
cells as optimal responders. We then introduced into each
line a plasmid containing a luciferase reporter downstream
of multimerized Gli binding sites and a minimal promoter
[20]. An isolated stable clone of the 10T1/2 cell transfec-
tants (referred to as clone S12) gave a 10-20-fold up-regu-
lation of luciferase activity (Figure 1a) when stimulated
with Hh protein [21] for 24 hours. Using this assay system,
we screened 140,000 synthetic compounds at a concentra-
tions of 2-5 M and isolated several putative agonists. One
of these molecules - Hh-Ag 1.1 (Figure 1a,b) - was studied
further. Hh-Ag 1.1 exhibited half-maximal stimulation
(EC50) at around 3 M, and an activation maximum
(Amax) of approximately 35% compared to the Hh protein
control (Figure 1a). In the presence of sub-threshold sig-
naling levels of Hh protein (0.3 nM), the EC50 of Hh-Ag
1.1 was reduced to around 0.4 M and the Amax
approached 70% (Figure 1a).
We next tested whether expression of endogenous Hh-
responsive genes was stimulated by the agonist. Using
quantitative PCR, Hh-Ag 1.1 was shown clearly to elevate
the expression of Gli1 and  Ptc1 in a dose-dependent
manner (Figure 1c).
Chemical modifications increase potency
In an effort to improve the potency of Hh-Ag 1.1, over 300
derivatives were synthesized and tested in the cell-based
reporter assay. The relative potencies of the most active
derivatives - 1.2, 1.3, 1.4 and 1.5 - are shown in Figure 1d.
The most potent, Hh-Ag 1.5, had an EC50 of approximately
1 nM. Thus, potency was increased over 1000-fold by chem-
ical modification. The structures of compounds 1.2 and 1.3
are shown in Figure 1e. Hh-Ag 1.2 was the most stable
derivative in vivo and in vitro (data not shown) and was used
for most cell-based assays. Hh-Ag 1.3 showed lower toxicity
in embryonic tissue cultures (data not shown) and was used
for the neural plate explant assays described below. These
experiments suggest that the agonist may have many of the
properties of the Hh ligand. To specifically test this, we used
two established in vitro assay systems that detect the effects
of Hh on primary neuronal precursors.
In vitro assay of neuronal precursors
Proliferation activity of the agonist
It has recently been shown that primary neonatal cerebellar
granule neuron (CGN) precursors proliferate in response to
Hh stimulation [2]. To determine whether the Hh agonist
could elicit this response, we monitored [3H]-thymidine
incorporation of cultured rat CGN precursors treated with
Hh protein, Hh-Ag 1.1, Hh-Ag 1.2, or vehicle (DMSO). The
original active molecule, Hh-Ag 1.1, stimulated thymidine
incorporation at 5 M, but not at 1.75 M (Figure 1f). The
extent of proliferation was around 50% of that seen with a
high dose of Hh protein (50 nM). Hh-Ag 1.2 stimulated
proliferation at 300 nM and 100 nM to levels comparable to
those seen with Hh protein (Figure 1f). These data demon-
strate that the agonists can elicit a biological response in
primary cells similar to that produced by Hh protein.
Morphogenic activity of the agonist 
Neural progenitors within the intermediate region of the
chick neural plate (Figure 2a) respond to increasing concen-
trations of Hh protein by adopting specific fates. The iden-
tity of these cells can be assessed by their distinct expression
patterns of a set of transcription factors [2]. Three of these
transcription factors - Pax7, MNR2 and Nkx2.2 - whose
expression is differentially sensitive to increasing concentra-
tions of Hh protein were assayed in response to varying
concentrations of the agonist (Hh-Ag 1.3). The dorsal spinal
cord marker Pax7 is normally repressed by low concentra-
tions of Hh [22]. Pax7 expression was extinguished by 1-10
nM agonist (Figure 2b-f). Higher concentrations of agonist
(10-200 nM) induced expression of the motor neuron
progenitor marker MNR2 (Figure 2b,g-j), and yet higher
concentrations (20 nM–1 M) induced the most ventral
interneuron progenitor marker Nkx2.2 (Figure 2b,k-n). This
dose-dependent profile of expression closely resembles the
response achieved by increasing concentrations of Hh
protein [22-24], demonstrating that the Hh agonist mimics
the concentration-dependent inductive activity of Hh on
neural precursors.
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To explore the site of action of the Hh agonist within the Hh
pathway, we developed an in vivo assay for the agonist that
would allow us to test its activity in Shh- and Smo-mutant
mouse embryos in utero. First, we compared the expression of
Ptc1 in vehicle- and agonist-treated Ptc1lacZ/+ mouse embryos
[25]. The Ptc1lacZ/+ mouse expresses -galactosidase under
control of Ptc1-regulatory elements and thus reports Hh-
pathway activity in mouse tissues. Hh-Ag 1.2 (Figure 1e) was
chosen for study on the basis of its relatively low toxicity,
long serum half-life and ability to cross the placenta (data
not shown). Hh-Ag 1.2 was delivered by oral gavage to preg-
nant mice at 7.5 and 8.5 days post coitum (7.5 and 8.5 dpc).
Embryos were collected at embryonic day (E) 9.5 and ana-
lyzed by staining with the -galactosidase chromogenic sub-
strate X-gal. In vehicle-treated embryos, Ptc1 expression was
confined primarily to the ventral neural tube (Figure 3a,c). In
embryos treated with Hh-Ag 1.2, however, expression of
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Figure 1  
A Hh-signaling agonist identified in a cell-based small-molecule screen. (a) A luciferase-based reporter assay of Hh signaling, showing a dose-response
curve for the following: Hh protein (Hh); the small-molecule agonist Hh-Ag 1.1; Hh-Ag 1.1 in the presence of 0.3 nM Hh protein (Hh-Ag 1.1 + low
Hh); or 0.3 nM Hh protein alone (low Hh). Data points represent the averages (n = 4) with standard deviations less than 15%. (b) The structure of
Hh-Ag 1.1. (c) The output of a quantitative PCR analysis of Ptc1 and Gli1 mRNA levels from C3H10T1/2 cells exposed for 18 hours to an increasing
dose of Hh-Ag 1.1. Data are graphed as relative activation versus Hh-Ag 1.1 concentration (M). The 0 to 100% range was set using data from cells
treated with 0 or 25 nM Hh protein; fold inductions for levels of Ptc1 and Gli1 mRNA were determined using GAPDH mRNA levels as internal
standards. Each data point represents an average (n = 4) with standard deviation shown by error bars. (d) A luciferase-based reporter assay of Hh
signaling showing dose-response curves (with concentrations in nM) for Hh protein and the five agonist compounds Hh-Ag 1.1, 1.2, 1.3, 1.4 and 1.5.
Graphs are representative of multiple assays of these compounds. Data points represent the averages (n = 2) with standard deviations less than 15%.
(e) Structures of Hh-agonist derivatives; 1.2 is a methylated analog, and 1.3 a methylated analog with a para-pyridyl moiety. (f) A proliferation assay of
Hh-responsive primary neuronal precursors from postnatal day 4 rat cerebellum. [3H]-thymidine incorporation was measured 24 hours after the
addition of the vehicle dimethyl sulfoxide (‘vehicle’), Hh protein, or agonist. Hh protein was tested at 50 nM; Hh-Ag 1.1 was added at 5 and 1.75 M;
Hh-Ag 1.2 was added at 300 and 100 nM. Data points represent the averages (n = 4) with standard deviations depicted with error bars.
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Figure 2
The concentration-dependent response to Hh agonist of neural progenitor markers in neural plate explants. (a) The intermediate region of neural
plate was dissected from stage 10-11 chick embryos and cultured in the presence of varying concentrations of Hh-Ag 1.3 (agonist) for 22 hours.
Explants were then immunostained for Pax7, MNR2 and Nkx2.2 and the number of immunoreactive cells per explant was counted. (b) The average
number of immunoreactive cells per explant in response to increasing concentrations of Hh-Ag 1.3 (n = 6 explants). Error bars represent standard
deviations. (c-n) Confocal images of representative explants cultured in the presence of different concentrations of the agonist and stained for (c-f)
Pax7; (g-j) MNR2; and (k-n) Nkx2.2. Pax7 is expressed only at the lowest concentrations of the agonist (c,d), MNR2 at intermediate and high
concentrations (i,j), and Nkx2.2 only at high concentrations of agonist (n).
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throughout the adjacent mesoderm (Figure 3b,d). These
embryos also displayed open rostral neural tubes, similar to
those of Ptc1-/- embryos. These experiments demonstrate that
the agonist compound effectively activates Hh signaling in
vivo following oral administration.
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Figure 3
In vivo assays of an Hh agonist. (a-d) The Hh agonist Hh-Ag 1.2 up-regulates Hh signaling in mouse embryos in utero. Expression of Ptc1lacZ in E9.5
Ptc1lacZ/+ embryos after treatment with vehicle (a,c) or Hh-Ag 1.2 (b,d). (a,b) Lateral views of whole embryos stained with X-gal; (c,d) transverse sections
through E9.5 embryos following X-gal staining. Ptc1 expression is dorsally expanded throughout the ventral neural tube and adjacent mesoderm in
agonist-treated embryos (compare b,d with a,c). Note the open neural tube in the head of these embryos (b). (e-p) The agonist complements the loss
of Shh but requires Smo to activate Hh signaling in utero. (e-l) Whole-mount in situ hybridization analyses of the expression of Ptc1 gene in E8.5 embryos
(n = 4); (e-h) ventral anterior views, and (i-l) ventral posterior views, of embryos heterozygous (e,f,i,j) or homozygous (g,h,k,l) for an Shh-null allele.
(m-p) Lateral views of X-gal staining of Ptc1lacZ expression in E8.5 Ptc1lacZ/+ embryos (n = 4) heterozygous (m,n) or homozygous (o,p) for a Smo-null
allele. (e,g,i,k,m,o) Vehicle-treated embryos; (f,h,j,l,n,p) Hh-Ag 1.2- (agonist-) treated embryos. Red arrows in (e-h) indicate the partial rescue of midline
structures in Shh-/- embryos (g) by agonist treatment (h). Black arrowheads in (e-l) indicate expression in the midline.
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Having established an in utero assay for Hh signaling, we
next investigated whether the agonist could rescue aspects
of  Shh- or  Smo-mutant phenotypes, by monitoring lacZ
expression in Smo-/- Ptc1lacZ/+ embryos [26] and Ptc1 mRNA
levels in Shh-/- embryos.
Pregnant mice from Shh+/- and  Smo+/- intercrosses were
treated by oral gavage with vehicle or agonist (15 mg/kg) at
6.5 and 7.5 dpc. Embryos were collected at 6-8 somite stages
(E8.5) when the midline defects are first detectable in both
Shh-/- and Smo-/- embryos, but prior to any general retarda-
tion of growth and development [26,27]. In both Shh+/- and
Smo+/- Ptc1lacZ/+ embryos, Ptc1 was detected in ventral neural
tube, somites and lateral plate mesoderm (Figure 3e,i,m).
Treatment with the agonist dramatically enhanced and
expanded the expression of Ptc1 in these heterozygous
embryos (Figure 3f,j,n). This was consistent with what we
have observed in wild-type embryos (Figure 3a-d). It is
worth noting that the agonist-treated embryos exhibited
overgrowth of the headfolds and hindbrain, reminiscent of
Ptc1-/- embryos (compare Figure 3e,m with f,n).
Shh-/- and Smo-/- embryos at this stage (6-8 somites) started
to show fused ventral lips of the cephalic folds, and a single
continuous optic vesicle, indicating lack of a clearly defined
midline (red arrow, Figure 3g, and data not shown). As
expected, Ptc1 expression was not detected in the ventral
neural tube of the vehicle-treated Shh-/- embryos (arrow-
head, Figure 3g), whereas expression was seen in lateral
plate mesoderm and weakly in somites (Figure 3g,k). This is
most likely due to Ihh signaling in these tissues [26]. Both
Shh and Ihh signaling were dependent on Smo, however,
because  Ptc1 expression could not be detected in Smo-/-
embryos (Figure 3o). 
Following agonist treatment, we observed that the neural tube
and somite expression of Ptc1 in Shh-/- embryos was greater
than vehicle-treated wild-type levels (compare Figure 3h,l
with e,i). The midline defects in Shh-/- embryos were at least
partly rescued by agonist treatment (compare Figure 3g and h;
red arrows). Like Shh+/- embryos,  Shh-/- embryos had over-
grown headfolds after administration of the Hh agonist
(Figure 3f and h). In contrast, agonist treatment had no
detectable effect on either morphology or Ptc1 expression in
Smo-/- embryos (compare Figure 3o and p). In summary, these
studies demonstrate that agonist activity in vivo does not
depend upon Shh, but that Smo is absolutely required.
Mechanism of action
Chemical epistasis studies
We sought to determine the level at which the agonist acts in
the Hh pathway, in cultured cell assays. To begin addressing
this question, we used the Hh reporter cell line to conduct
competition experiments between the Hh agonist and
known Hh- signaling antagonists that block the pathway at
different levels (Figure 4a). These include: a Hh-protein-
blocking antibody, 5E1 [23]; a natural product derivative,
cyclopamine [9,10] that has recently been shown to act
downstream of Ptc, perhaps at the level of Smo [11];
a recently identified synthetic small-molecule inhibitor,
Cur61414, which has inhibitory properties similar
to cyclopamine [17]; and forskolin, an adenylate
cyclase/protein kinase A activator that is thought to block
Hh signaling by stimulating degradation of members of the
Gli family of transcriptional activators [2].
The Hh-blocking antibody 5E1 had no effect on pathway
activation by the agonist (Figure 4b), while forskolin
(Figure 4c), cyclopamine (Figure 4d) and Cur61414
(Figure 4e), were all inhibitory. The lack of inhibition by
5E1 eliminates the possibility that the small molecule
agonist activates signaling indirectly via stimulation of Hh
expression. Furthermore, this supports the data showing
that the agonist can activate signaling in Shh-/- embryos
(Figure 3) and suggests that the agonist function is not only
downstream of the Hh protein but also independent of the
endogenous Hh-signaling modulators, Tout veloux and
HIP, that act via the Hh ligand [2]. The competition experi-
ment with forskolin showed identical inhibition curves for
Hh protein and the agonist, strongly suggesting that the
action of the small molecule is upstream of the protein-
kinase-A-sensitive step in the pathway. In contrast, the com-
petition experiments with cyclopamine (Figure 4d) and
Cur61414 (Figure 4e) showed that Hh protein and the
agonist differ in their sensitivity to these antagonists. Specif-
ically, the agonist appears somewhat resistant to the
inhibitory effect of cyclopamine and Cur61414. Identical
results were seen using the slightly less active cyclopamine-
related natural compound jervine, and the more potent syn-
thetic derivative of cyclopamine, KAAD-cyclopamine (data
not shown). These results argue that the agonist activates
the pathway downstream of the Hh-Ptc interaction while
cyclopamine, Cur61414 and the agonist may act at a similar
level in the Hh-signaling cascade.
Regulation of Ptc and Smo by Hh protein and Hh agonist
Recent work in Drosophila tissue culture has shown that
endogenous Ptc and Smo proteins are differentially affected
by the addition of Hh to the growth medium [5]. Ptc was
destabilized, while Smo accumulated following post-transla-
tional modification. To test whether similar phenomena
occur in mammalian cells with Hh protein and agonist, we
generated stable cell lines expressing two epitope-tagged pro-
teins, Ptc coupled to green fluorescent protein, Ptc-GFP, and
Smo coupled to a fragment of influenza hemagglutinin,
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Figure 4
Analysis of the agonist’s site of action, using characterized Hh-pathway antagonists. (a) The Hh-signaling pathway. The major components are shown,
along with the suspected sites of action of four antagonists: 5E1, the Hh-ligand-binding/blocking monoclonal antibody; cyclopamine, the natural
product inhibitor, activity of which maps downstream of Ptc; forskolin, the adenylate cyclase activator that functions via protein kinase A to activate
destruction of Ci/Gli; and a recently identified Hh-signaling antagonist Cur61414. Lines with arrowheads represent activation and blunt-ended lines
represent repression. (b-e) Luciferase-based reporter assays of Hh signaling showing inhibitory dose response on cells activated by Hh protein
(10 nM) or Hh-Ag 1.2 (200 nM) of (b) 5E1; (c) forskolin; (d) cyclopamine; and (e) Cur61414. Data points represent the averages (n = 3) with
standard deviations depicted by error bars. 
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(d) (e)HA-Smo. Figure 5a shows an immunoprecipitation (anti-
GFP) plus protein blot (anti-Ptc) analysis of extracts from
these cells treated for 4, 8 and 24 hours with vehicle, 25 nM
Hh protein or 0.2 M Hh agonist (see Figure 1e; Hh-Ag 1.2).
This experiment shows that Ptc-GFP appears to be destabi-
lized by Hh protein but not by the agonist. Similar results
were seen at higher doses of agonist (up to 2 M) and in
several independent lines (data not shown). These data
further support the idea that Hh protein and the agonist act
in distinct ways to stimulate the pathway.
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Figure 5
The effects of Hh protein and agonist on vertebrate Smo and Ptc proteins. A stable cell line expressing Ptc-GFP and HA-Smo retroviral constructs
was generated to evaluate the effects of Hh protein versus agonist on the Hh receptor components. (a) Anti-Ptc protein blot of anti-GFP
immunoprecipitates, fractionated by SDS-polyacrylamide gel electrophoresis, from cells treated with vehicle (lanes 1,4,7), 25 nM Hh protein (lanes
2,5,8) or 0.2 M Hh-Ag 1.2 (agonist; lanes 3,6,9), for 4 hours (lanes 1-3), 8 hours (lanes 4-6) or 24 hours (lanes 7-9). (b) Anti-HA protein blot of cell
extracts, fractionated by SDS-polyacrylamide gel electrophoresis, from cells treated with vehicle (lanes 1,4,7,10), 35 nM Hh protein (lanes 2,5,8,11)
or 0.5 M Hh-Ag 1.2 (agonist; lanes 3,6,9,12), for 2 hours (lanes 1-3), 5 hours (lanes 4-6), 8 hours (lanes 7-9) or 20 hours (lanes 10-12). (c) Anti-HA
protein blot of cell extracts, fractionated by SDS-polyacrylamide gel electrophoresis, from cells treated with vehicle (lanes 1,4), 35 nM Hh protein
(lanes 2,5), or 0.5 M Hh-Ag 1.2 (agonist; lanes 3,6), for 5 hours (lanes 1-3) or 8 hours (lanes 4-6). Cells used in (c) were also treated with
cycloheximide to block new protein synthesis. Blots in (b) and (c) were reprobed with anti-tubulin antibody as a sample loading control. (d) Anti-HA
protein blot of cell extracts, fractionated by SDS-polyacrylamide gel electrophoresis, from cells treated with decreasing concentrations of Hh protein
(lane 1, 100 nM; lane 2, 50 nM; lane 3, 25 nM; lane 4, 12.5 nM; lane 5, 6.25 nM; lane 6, 3.12 nM), or with vehicle (lane 7), or with increasing
concentrations of Hh-Ag 1.2 (agonist; lane 8, 15 nM; lane 9, 31.25 nM; lane 10, 62.5 nM; lane 11, 250 nM; lane 12, 500 nM; lane 13, 1 M) for 22
hours. All blots were visualized by autoradiography using anti-HRP (horse radish peroxidase) secondary antibodies and a chemiluminescence reagent
kit (Amersham).
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(c) (d)Figure 5b shows an immuno-blot (anti-HA) of total
extracts from HA-Smo-expressing cells treated for 2, 5, 8
and 20 hours with vehicle, 35 nM Hh protein or 0.5 M
Hh agonist. In contrast to the results with Ptc-GFP, incuba-
tion of cells with both Hh protein and the small-molecule
agonist resulted in the apparent accumulation of HA-Smo
protein after 5 hours of incubation. To test whether the
accumulation of HA-Smo in response to Hh protein or the
agonist required protein synthesis, a similar study was per-
formed in the presence of cycloheximide (Figure 5c).
Under these conditions, HA-Smo accumulation was
detectable 5 hours after addition of either Hh protein or
the agonist (Figure 5c); this result argues that the effect of
Hh protein and the agonist on HA-Smo levels does not
require new protein synthesis. Finally, with increasing con-
centrations of Hh protein and the agonist there is a clear
dose-dependent increase of HA-Smo levels (Figure 5d).
These effects on epitope-tagged Smo protein were observed
in multiple lines (data not shown). Taken together, these
data suggest that Hh protein and the agonist share the
ability to stabilize Smo, but only Hh protein can destabi-
lize Ptc. Yet the agonist is fully capable of activating the full
signaling pathway.
Testing Smo as the molecular target
Binding in whole cells
Our biochemistry experiments (above) show that the agonist
modulates Smo levels, and thus may activate Hh signaling
by directly binding Smo. To explore this possibility we tested
whether a tritiated form of the agonist analog Hh-Ag 1.5
could form a complex with Smo, when Smo is transiently
overexpressed in 293T cells. Figure 6a shows immuno-
precipitable counts of extracts from cells incubated at 37°C
for 2 hours with 5 nM [3H]-Hh-Ag 1.5 either in the absence
(columns 1-3) or presence of competitors (columns 4-9). 
Immunocomplexes from untransfected control and
-adrenergic-receptor transfected cells did not contain sig-
nificant counts (Figure 6a, columns 1, 2). Immunocom-
plexes derived from cells expressing Smo (Figure 6a,
column 3) resulted in the recovery of approximately 40,000
of the 800,000 added counts, however. To test the speci-
ficity of this apparent Hh-Ag/Smo complex, cells were incu-
bated with 5 M (1000-fold molar excess) of unlabeled Hh
Ag 1.5 or an unlabeled, signaling-inactive but structurally
similar compound, an Hh-Ag 1.1 derivative that has a two-
carbon linker in place of the cyclohexane ring (Figure 6a;
Hh-Ag 1.5, column 4; Hh-Ag control, column 5). The addi-
tion of the unlabeled Hh-Ag 1.5, but not the inactive Hh-Ag
1.1 derivative agonist control, resulted in the complete
absence of counts in the immunocomplex. These results
suggest that a stable, specific interaction can form between
Smo and the Hh agonist.
It has been shown that the Hh-pathway antagonists
cyclopamine and Cur61414 block signaling in a Ptc-inde-
pendent manner [11,17] and therefore may act directly on
Smo. Having established a binding assay for a small-mole-
cule agonist binding to Smo-expressing cells, we next tested
whether the Hh antagonists could selectively compete out
binding of [3H]-Hh-Ag 1.5. To perform theses studies, Smo-
overexpressing 293T cells were incubated for 2 hours at
37°C with 5 nM [3H]-Hh-Ag 1.5 in the presence of either
KAAD-cyclopamine at 5 M (Figure 6a, column 6), the
related but inactive plant compound tomatadine at 5 M
(Figure 6a; Antag control 1, column 7), Cur61414 at 5 M
(Figure 6a, column 8), or a related but inactive Cur61414
derivative (Figure 6a; Antag control 2, column 9) at 5 M.
These data show that the Hh-signaling inhibitors, but not
structurally related inactive compounds, can significantly
compete with the binding of the Hh agonist to Smo-
expressing cells. This supports the model that all of these
small-molecule modulators of Hh signaling are direct
ligands of Smo.
We next asked whether a derivative of the Hh agonist carry-
ing a photoactivatable crosslinker could be coupled directly
to Smo, to facilitate further biochemical characterization of
the binding site. To perform this experiment we synthesized
a tritiated diazirine derivative of Hh-Ag 1.2 with an EC50 in
the cell-based assay of 35 nM (data not shown). We incu-
bated this compound at 0.5 M with HA-Smo- or control,
GFP-transfected 293T cells and subsequently ultraviolet-
irradiated them to initiate crosslinking. Fractionation by
SDS-polyacrylamide gel electrophoresis and autoradio-
graphy of the resulting immunocomplexes from these cells
showed crosslinking exclusively to HA-Smo, but with an
efficiency of less than 1% (data not shown). This result
demonstrates that a Hh-agonist derivative can be covalently
crosslinked to Smo in living cells. More efficient crosslinkers
are required to extend these studies, however.
Cell-free membrane-binding assays
To test whether the Hh agonist could interact with Smo in
vitro, we transiently overexpressed murine Smo, murine
Ptc, rat 2-adrenergic receptor and GFP in 293T cells, har-
vested membranes and performed a filtration membrane-
binding assay in a 96-well plate with [3H]-Hh-Ag 1.5 added
at 2 nM. Figure 6b shows a bar graph of the bound counts
from these binding assays (murine Smo, column 1; GFP,
column 2; AR, column 3; murine Ptc1, column 4; and a
no-membrane plate control, column 5). The no-membrane
control (column 5) was included to show the degree of
non-specific binding to the filter-plate apparatus. The Smo-
containing membranes (column 1) are the only samples
that exhibit significant binding above that seen in the
absence of membranes. 
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experiment in the presence and absence of a 1000-fold molar
excess of unlabeled agonist (2 M). The addition of
‘cold’ compound completely competed out these counts
(Figure 6c, column 1 compared to column 2). To control for
this observation, we added an unlabeled, inactive Hh agonist
to the binding assay at 2 M (a 1000-fold molar excess). This
compound was unable to compete out the binding of [3H]-
Hh-Ag 1.5 to the Smo-containing membranes (Figure 6c,
column 3). These results argue that Smo and the agonist form
a specific complex in vitro, as predicted by the whole
cell/immunocomplex binding assay (Figure 6a).
Having established an in vitro binding assay for the Hh
agonist to Smo, we next tested whether the Ptc-independent
Hh antagonists could selectively compete with the interac-
tion. Binding was assayed in the presence of KAAD-
cyclopamine at 10 M (Figure 6c, column 4), tomatadine at
10 M (Figure 6c; Antag control 1, column 5), Cur61414 at
10 M (Figure 6c, column 6), or the inactive Cur61414 deriv-
ative (Figure 6c; Antag control 2, column 7) at 10 M. These
data show that the Hh-signaling inhibitors, but not struc-
turally related inactive compounds, can significantly compete
with the binding of the Hh agonist to Smo membranes. 
Kinetics, saturation and competition binding analysis
Next, we sought to generate association, dissociation and
saturation-binding curves, in order to derive affinity
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Figure 6
Assessing whether Smoothened is the molecular target of the Hh
agonist. (a) The number of counts per minute (cpm) precipitated from
an immunocomplex binding assay of 293T cells incubated with
[3H]-Hh-Ag 1.5. Anti-HA (columns 1,3-9) or anti-v5 (column 2)
immunocomplexes were isolated from 293T cells that were
untransfected (column 1) or transfected with expression constructs
encoding a rat 2-adrenergic receptor cDNA carrying a v5 epitope tag
(column 2; AR), or an HA-epitope-tagged Smo cDNA (columns 3-9).
Prior to cell lysis and immunoprecipitations, these cells were incubated
with 5 nM [3H]-Hh-Ag 1.5 alone (columns 1-3) or with 5 nM
[3H]-Hh-Ag 1.5 in the presence of 5 M of various unlabeled
compounds (columns 4-9): Hh-Ag 1.5 (column 4); an inactive Hh-Ag
1.1-derivative containing a two-carbon linker instead of the cyclohexane
ring (Ag control, column 5); the potent natural product Hh-signaling-
inhibitor derivative KAAD-cyclopamine (column 6); the inactive natural
product tomatadine (Antag control 1, column 7); the synthetic Hh-
signaling inhibitor Cur61414 (column 8); or an inactive derivative of
Cur61414 (Antag control 2, column 9). Standard deviations (n = 2) are
represented by error bars. (b,c) Filtration membrane-binding assay
using [3H]-Hh-Ag 1.5 (2 nM) and membranes (approximately 5 g
protein) from 293T cells transfected with different cDNA constructs.
(b) Bound [3H]-Hh-agonist (cpm) when using membranes from cells
transfected with murine Smo (column 1); GFP (column 2); rat 2-
adrenergic receptor (AR, column 3), and murine Ptc1 (column 4).
A no-membrane control (column 5) is also included, to demonstrate
the level of nonspecific binding associated with the filtration plate
apparatus. (c) A competition experiment using membranes from cells
transfected with murine Smo and incubated with [3H]-Hh-Ag 1.5 (2 nM)
in the presence of various unlabeled compounds: no competitor 
(-, column 1); 2 M unlabeled Hh-Ag 1.5 (column 2); 2 M inactive
Hh-Ag 1.1 derivative (Ag control, column 3); KAAD-cyclopamine
(column 4); tomatadine (Antag control 1, column 5); Cur61414 (column
6); or an inactive derivative of Cur61414 (Antag control 2, column 7).
Standard deviations (n = 4) are represented by error bars.constants for the interaction of the Hh agonist and Smo. To
control for nonspecific binding we used either Cur61414 or
Hh-Ag 1.5 as unlabeled competitors. Similar results were
generated if control membranes (from cells transfected with
GFP, AR, or Ptc) were used to define the non-specific level
(data not shown). 
First, we performed a kinetic analysis to establish the
reversibility of the binding reaction and the approximate
incubation time required for equilibrium binding studies.
Association assays were performed at 37°C by combining
2 nM [3H]-Hh-Ag 1.5 with Smo-containing membranes for
various times prior to harvesting and counting. Dissociation
studies were initiated by adding 2 M unlabeled Hh-Ag 1.5
after 2 hours of association. Samples were then incubated for
1-26 hours prior to harvesting and counting. Figure 7a shows
the association and dissociation phases of agonist binding to
Smo-containing membranes. Using the Prism GraphPad
software, these data were fit to one-phase exponential associ-
ation and decay curves, respectively, and gave an association
t½ of approximately 1 hour and a dissociation t½ of approx-
imately 10 hours. These results demonstrate that the binding
of the agonist to Smo is reversible and that equilibrium
binding will require binding reaction times of approximately
50 hours (five times the t½ of dissociation). 
Next, we performed a saturation binding experiment. To
establish total, nonspecific, and specific binding curves
(Figure 7b), we added a range of [3H]-Hh-Ag 1.5 concentra-
tions (0.01-3 nM) in the presence or absence of unlabeled
Hh-Ag-1.5 at 2 M. Identical results were seen if Cur61414
at 10 M was used as the competitor (data not shown). On
the basis of the binding kinetics, incubations were carried
out for approximately 45 hours at 37°C, to allow for equi-
librium to be reached. Using the Prism GraphPad software
to perform non-linear regression analysis and curve fitting,
we concluded that the data best fit a simple one-site binding
model with a predicted Kd of 0.37 nM for Hh-Ag 1.5. This
Kd is in general agreement with the EC50 values observed in
the cell-based assay (0.37 nM as compared to 1 nM).
To further validate our binding results, we performed a
competition assay using several agonist derivatives across a
range of concentrations (0.01 nM to 1 M). Figure 7c shows
the competition curves for Hh-Ag 1.5, Hh-Ag 1.3, Hh-Ag
1.2, Hh-Ag 1.1, and the signaling-inactive Hh-Ag 1.1 deriva-
tive described above. With the exception of the inactive
derivative, these compounds all compete out the binding of
[3H]-Hh-Ag 1.5 (0.4 nM) to the Smo-containing mem-
branes. These data are best fit to a single-binding-site com-
petition model that predicts the following Ki values: Hh-Ag
1.5, 0.52 nM; Hh-Ag 1.3, 8.4 nM; Hh-Ag 1.2, 22 nM; and
Hh-Ag 1.1, 96 nM. These Ki values are in general agreement
with the agonist EC50 values in cell culture for these
compounds, with the exception that the Hh-Ag 1.1 com-
pound is not as potent in signaling assays (EC50 2 M) as its
Ki (96 nM) might predict. This suggests an uncoupling of
binding and signaling for certain agonists. Although
binding affinities and signaling efficacy can correspond for
certain ligand/receptor complexes, exceptions often arise
[28] because binding affinity does not necessarily measure
the ability of a compound to induce an active receptor con-
formation. As a control for these binding studies, identical
competition experiments were performed with membranes
from cells transfected with GFP, or with the -adrenergic
receptor. No specific binding or apparent competition was
seen under these conditions (data not shown).
We next compared binding of KAAD-cyclopamine,
Cur61414 and Hh-Ag 1.5 to a constitutively active mutant
of Smo (Smoact) or to wild-type Smo (Smowt). The two Hh-
signaling antagonists, KAAD-cyclopamine and Cur61414,
have shown decreased potency on Smoact-expressing cells,
leading to the speculation that they may bind this mutant
form of Smo less well than the wild-type form [11,17]. We
sought to determine whether the Hh agonist binds Smoact
with a higher affinity, an observation seen with certain
ligands and constitutively active mutants of GPCRs [29]. To
perform this experiment, we isolated membranes from cells
transfected with a cDNA construct encoding a tryptophan-
to-leucine mutation at residue 539 (W539L) of murine
Smo. This oncogenic mutation has been found in human
basal cell carcinoma [3] and the correspondingly mutated
protein is capable of ligand-independent activation of the
Hh pathway in cell-culture assays [11]. A kinetic and satura-
tion binding assay with Smoact-containing membranes
showed that this mutant protein binds the Hh agonist with
an affinity identical to that of Smowt (data not shown). 
Using Smoact- and Smowt-containing membranes, we then
performed competition binding studies by adding increas-
ing concentrations of unlabeled Hh-Ag 1.5, KAAD-
cyclopamine or Cur61414 in the presence of [3H]-Hh-Ag
1.5 (0.4 nM). These binding curves (Figure 7d) can be fit to
a single-site competition model. Although the Ki for Hh-Ag
1.5 on Smoact-containing membranes was essentially identi-
cal to that observed for Smowt-containing membranes
(approximately 0.5 nM), the Ki values of the Hh antagonists
were seven-fold higher on the Smoact- compared to the
Smowt- containing membranes for both KAAD-cyclopamine
(38.3 nM versus 5.8 nM) and Cur61414 (309 nM versus
44 nM). These results strongly support the model, initially
hypothesized for cyclopamine [11], that the reduced
potency observed for Hh antagonists on Smoact-expressing
cells is directly due to a reduced affinity of the antagonist for
the mutated Smo protein. The agonist, on the other hand,
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affected by this gain-of-function Smoact mutation. 
Discussion
Hh signal transduction has been the focus of intense
research over the past decade due to the central role it plays
in development and its emerging biomedical relevance in
areas ranging from regenerative medicine to oncology
[2,30]. Our goal in these studies was to isolate and charac-
terize small-molecule modulators of Hh signaling in order
to understand better the regulation of pathway activation
and to generate potential therapeutics. Our work shows
firstly that it is possible to identify potent small molecule
agonists of Hh signaling, secondly that these compounds
can mimic the effects of recombinant Hh protein in multi-
ple assays used to define the properties of Hh signaling,
thirdly that these compounds act by binding directly to
Smo, and finally that two Ptc-independent inhibitors of Hh
signaling compete for this binding to Smo, strongly suggest-
ing they too act directly on Smo. 
Models of Smo-ligand interaction 
To interpret the results of the competition binding studies,
we assume that the mutation in Smoact, like those in consti-
tutively activate mutants of other GPCRs [29], indirectly
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Figure 7
[3H]-Hh-agonist kinetic, saturation and competition binding analysis with Smo-containing membranes. (a) The association (solid line) and dissociation
(broken line) time courses for the binding of [3H]-Hh-Ag 1.5 to membranes from Smo-overexpressing 293T cells. The arrow denotes the time at
which 2 M unlabeled [3H]-Hh-Ag 1.5 was added to initiate dissociation studies. (b) The total (squares), nonspecific (triangles) and specific (circles)
binding (in cpm) of [3H]-Hh-Ag 1.5 to membranes from Smo-overexpressing 293T cells. Total and specific binding data were derived in the absence
and presence of 2 M unlabeled Hh-Ag 1.5, respectively. The specific curve (red) represents the difference between these curves. Similar specific
curves resulted when control membranes or a no-membrane control plate was used to define the nonspecific binding, or if 10 M Cur61414 was
used as the competitor. A dissociation binding constant (Kd) of 0.37 nM is predicted from this single site binding isotherm. (c) A competition assay
of [3H]-Hh-Ag 1.5/Smo binding by a set of agonist derivatives including Hh-Ag 1.5 , Hh-Ag 1.3, Hh-Ag 1.2, Hh-Ag 1.1, and an inactive Hh-agonist
derivative. (d) A competition binding study showing the properties of the binding of KAAD-cyclopamine, Cur61414 and Hh-Ag 1.5 to wild-type
Smo, Smowt, and a constitutively active Smo mutant protein, Smoact, which contains an activating W539L amino-acid substitution. Competition
curves on Smowt are shown by broken lines and the competition curves on Smoact by solid lines. Standard deviations (n = 4) are represented by
error bars for all data points.
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(c) (d)influences ligand binding by creating a change in the
normal equilibrium between the different conformations
of Smo. Thus, the mutation would not directly influence
the binding pocket for either ligand. A simple two-state
model (Figure 8a) predicts that the agonist (Ag, green
square) and the antagonist (Ant, pink circle) compete for
the same site on Smo to activate or inactivate Hh-pathway
signaling. It also suggests that antagonists should bind
Smoact with a lower affinity than they bind Smowt, while
the agonist should bind with a higher affinity, as it prefers
the active conformation. Such a model cannot accommo-
date our observations with the gain-of-function Smo
mutant. Thus we introduce a ternary complex model
(Figure 8b), used traditionally to describe the behavior of
GPCRs in binding studies with agonist and antagonists
[31], as well as constitutively active receptors [29]. The
ternary complex model for Hh signaling suggests that there
are two independent binding sites on Smowt, one specific
for the agonist and another specific for antagonists.
Binding at either site would decrease the affinity for inter-
actions at the other site (allosteric binding with high nega-
tive cooperativity). The agonist-bound form represents the
normal activated state, while the antagonist-bound form is
considered the inactive conformation. There are also other
conformations that would not be bound, or would be
transiently bound, by both ligands. A signaling pathway
coupler, or effector (in blue), is proposed to bind the acti-
vated state of Smowt so as to generate a complex competent
to initiate Hh signaling. Throughout the discussion the
term ‘coupler/effector’ is used to describe an unknown
molecule that binds activated Smo in such a way as to
trigger signal transduction. The model further suggests that
the Smoact protein resides in a stable conformation in the
absence of agonist that is capable of forming an active
coupler/effector complex resistant to antagonist, but not
agonist, binding. 
Specifically, our data suggest that the agonist binds and
stabilizes (or induces) an active signaling state of Smo
while the antagonists bind and stabilize (or induce) an
inactive form. Furthermore, the gain-of-function Smo
mutation renders the protein less sensitive to the
inhibitors, presumably because the amino-acid substitu-
tion directly stabilizes or induces an active conformation.
On the basis of a simple two-state model, one might
predict an increased affinity of the agonist for the mutant
form, but in our studies binding of the agonist, unlike the
antagonist, is not affected by the activating mutation, sug-
gesting that a more complex model requiring two binding
sites and perhaps multiple active conformations is needed
to account for the observations. Thus, we propose a varia-
tion of the classic ‘ternary complex model’ (Figure 8), a
decades-old paradigm that has provided the foundation
for describing ligand induced conformational changes of
GPCRs [31].
Briefly, if this model is applied to Hh signaling, it proposes
that, firstly, agonist and antagonists act at independent sites
to select active and inactive conformations of Smo; sec-
ondly, that Smo engages an undefined coupler/effector,
when it is in its signaling state; and finally, that the gain-of-
function mutant form of Smo, Smoact, adopts an abnormal
conformation that resembles the coupler/effector-bound
signaling state of Smo with low affinity for antagonists but
normal affinity for the agonist.
Activating Hh signaling through the GPCR-like Smo
receptor 
As a receptor class, GPCRs are considered excellent drug
targets because they are often regulated through interactions
with small natural ligands [32,33]. Specifically, studies of
classic GPCRs, such as the -adrenergic receptors, show that
in the absence of endogenous ligand (agonists) these recep-
tors exist in multiple interconvertible conformations that
are predominately inactive [34]. Upon exposure to their
natural ligands, however, the active receptor forms are pref-
erentially stabilized, allowing them to readily engage
G-protein couplers and to create signaling-competent com-
plexes. Multiple compound classes have been isolated on
the basis of their ability to compete for the binding of
-adrenergic receptors by their natural ligands. These com-
petitors can mimic the natural ligand activity (agonists) or
interfere with it (antagonists).
In addition to the binding sites for natural or endogenous
agonists (orthosteric sites), many GPCRs have also been
found to have allosteric sites [35]. These sites can bind
natural ligands, as in the case of Zn ions and heparin for
the dopamine and neurokinin receptors, respectively, or
bind synthetic drugs such gallamine, in the case of the
muscarinic receptors [35]. Binding of small molecules to
these allosteric sites can modulate activity of a receptor
without directly mimicking or competing out the interac-
tion of ligands to the orthosteric sites. In summary, GPCRs
have an array of potential regulatory binding sites, or
potential drug targets.
How does Smo compare with other GPCRs with regard to
the properties described above? Although there is clear
structural homology between Smo and other GPCRs,
endogenous ligands have yet to be discovered. Early models
of Hh signaling proposed a Hh-regulated Ptc-Smo complex
that directly controlled the conformation of Smo, making
endogenous ligands unnecessary. But recent studies argue
against this stoichiometric model [5,36], indicating that
perhaps natural ligands should be considered. Furthermore,
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are also equivocal. Although no compelling data have been
presented that directly link classic G-protein activation [37]
to the canonical Hh pathway involving Ci/Gli stimulation
[2], recent studies show that under certain conditions Smo
can engage G-protein subunits in a Ptc-dependent manner
[38] and that G-protein-mediated cAMP modulation may
underlie certain effects of Hh on neuronal tissue [39].
Finally, with respect to pharmacological properties, our
studies indicate that Smo behaves like a classic GPCR in
many regards and that the models used to describe this
large family of receptors can be applied to Hh signaling
(Figure 8). Two relatively novel concepts for Hh signaling
are raised by these GPCR models: firstly, the importance
of considering the active Smo-coupler/effector complexes
when modeling pathway regulation, and secondly the
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Figure 8
Models of small-molecule modulators binding to Smo. (a) The two-state model shows direct competition for a single binding site between the
agonist (Ag, green square) and the antagonist (Ant, pink circle). (b) The ternary complex model suggests that there are two independent sites, and
that agonist and antagonists are in a dynamic equilibrium (denoted by arrows) between Smo conformers bound at one site, both sites or not bound
by ligand. On the basis of experimental data, binding at either site would decrease the affinity of interaction at the other site (allosteric binding with
high negative cooperativity). A hypothetical signal transduction coupler, or effector, (the blue structure labeled X) is introduced in the ternary
complex model. A coupler/effector-bound form is considered to be the active signaling complex. According to the model, only single active agonist-
bound species of Smowt is seen (bottom left). For Smoact (bottom right), the model predicts that the activating point mutation, W539L, results in a
stable, distorted form of Smo that binds the antagonist poorly and has an increased affinity for the coupler/effector, even in the absence of agonist,
thus leading to elevated basal signaling. This mutant form can nevertheless bind agonist and assume a conformation like that of the normal activated
Smowt. Residue 539 is designated as either W for Smowt or as L in the Smoact mutant.
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GPCR models for Smo and potential mechanisms of
Ptc function
A recent study in Drosophila suggested that Hh stimulates
the pathway via Ptc degradation and, as a result, Smo is sta-
bilized through extensive phosphorylation at the plasma
membrane where it initiates signaling [5]. This led to specu-
lation that a Ptc-regulated phosphatase may control the sub-
cellular distribution and stability of Smo [5]. Although
suggestive, the studies in Drosophila did not establish that
phosphorylation, translocation or stabilization of Smo is
required for pathway stimulation. It is plausible that some
or all of these effects on Smo result from a feedback inhibi-
tion mechanism that targets the activated Smo receptor.
Interestingly, while we did observe stabilization of Smo by
Hh in our mammalian cell experiments (Figure 5), we did
not detect Smo phosphorylation or translocation to the
plasma membrane (data not shown). Perhaps the cellular
(or species) context dictates the degree to which the active
conformations of Smo are associated with such changes.
Thus, in considering models of Ptc function based on Hh-
stimulated effects it is important to consider whether the
form of Smo that is being observed is the active
(coupler/effector bound) signaling state, or perhaps a
downregulated and inactive form.
Several potential points for regulation by Ptc during the for-
mation of a Smo-coupler/effector complex are apparent in a
ternary complex model. The ideas proposed for the
Drosophila system, in which Ptc may affect the levels of Smo
or its subcellular localization, are easily accommodated. Ptc-
induced instability of Smo protein would indirectly reduce
the concentration of an active Smo-coupler/effector
complex. Furthermore, limiting access of Smo to its effector
through targeted vesicle trafficking would prevent a signal-
ing-competent complex from forming. Alternatively, Ptc
could more directly maintain Smo in an inactive state. On
the basis of our studies it is tempting to speculate that
native small molecules with properties similar to our
agonist and antagonists act directly on Smo in a Ptc-depen-
dent manner. These putative endogenous Smo modulators
could represent orthosteric or allosteric ligands.
The simplest model would have Ptc acting catalytically to
dock a natural antagonist directly onto (or remove an
agonist from) Smo. A more complex model would involve
Ptc restricting the distribution of Smo such that it is forced
into compartments containing the natural antagonists or
lacking the natural agonists. Finally, Ptc could control the
distribution of the endogenous small-molecule modulators
themselves. Ptc shares sequence homology with molecules
associated with vesicle trafficking and transporter activity,
namely SCAP and NPC1 [36,40-42]; if it also shares the
activities of these molecules, as suggested by a recent study
[36], then the possibility of the existence of endogenous
Smo ligands that are docked via Ptc should be explored. 
Therapeutic potential of a Hh-pathway agonist
Various studies in mammals have shown that Hh genes are
expressed in discrete areas of the adult organism and may
function in the normal maintenance of mature organ
systems [43-46]. In addition, the regenerative healing of
vascular and skeletal tissues following acute injuries appears
to be aided by re-activating the Hh-signaling cascade
[47,48]. Taken together, these observations suggest that the
Hh pathway may represent a point of intervention for treat-
ing certain degenerative disorders. Two recent studies in
models of Parkinson’s disease and peripheral nerve damage
support this claim, by demonstrating that pathway activa-
tion with a Hh-protein ligand has therapeutic value [49,50].
On the basis of our current understanding of these models
and the specific mechanism of action of the Hh agonists, we
predict that an agonist-derivative with low toxicity and
favorable pharmacokinetics would replicate these positive
results. As a drug, a Hh agonist would represent an attractive
alternative to an expensive Hh-protein therapeutic. Beyond
the economics, for disorders of the central nervous system a
small molecule with the potential to cross the blood-brain
barrier would eliminate the need for injections directly into
the brain, the current delivery mode for central nervous
system protein therapies.
Materials and methods
Chemical libraries and medicinal chemistry
The compound libraries used in our screens were purchased
from a number of commercial vendors and were primarily
generated by combinatorial chemistry approaches. The Hh-
agonist class was isolated from a library synthesized by
Oxford Asymmetry International, now EvotecOAI. The
derivatization of this compound class utilized standard pro-
cedures, the details of which will be published elsewhere.
Cultured cell line assays
TM3 and C3H10T1/2 cells (ATCC; Manassas, USA) were
maintained according to the instructions of ATCC. Stable
Hh-signaling reporter cell lines were established by G418
selection following transfection with a luciferase reporter
plasmid [20] containing the neomycin-resistance gene. Hh
signaling was monitored by plating cells at 70% confluence
in growth medium. After 24 hours the cells were changed to
0.5% serum-containing medium, and Hh protein or com-
pounds were added; 24 hours later the cells were either
monitored for luciferase activity using the Luc-lite assay kit
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for RNA isolation using an RNA isolation kit (Qiagen;
Valencia, USA). RNA was subjected to quantitative RT-PCR
analysis (Taqman; Applied Biosystems, Foster City, USA) uti-
lizing Gli1, Ptc1 and GAPDH primers and probes. Assays were
run on a Prism 7700 instrument (ABI; Applied Biosystems). 
Recombinant Hh protein
The Hh protein used in the studies described here was bac-
terially overexpressed amino-terminal human Shh modi-
fied at its amino-terminal cysteine by an octyl maleimide
moiety [21]. This lipophilic Shh form showed comparable
potency to native Shh in the cell-based reporter assay (data
not shown).
Retroviral cell lines
Mouse Smo and Ptc1 genes were introduced by a retroviral
approach utilizing the pLPCX vector (Clontech; Palo Alto,
USA) to limit the copy number per cell. Stable HA-Smo and
Ptc-GFP lines were established by puromycin selection fol-
lowing infection of TM3 cells with the respective retro-
viruses. TM3 cells expressing both epitope-tagged Ptc and
Smo were derived by infecting first with an HA-Smo con-
struct and subsequently with a Ptc-GFP construct. The levels
of Ptc were relatively low in these lines and a standard
immunoprecipitation procedure followed by western blot-
ting was required to detect the Ptc-GFP protein. The HA-Smo
protein was highly expressed and was easily detected in
western blots of whole cell extracts. The HA tag was sub-
cloned into the Smo gene so that it would reside immediately
after the Smo signal sequence. The GFP tag was inserted
before the stop codon of the Ptc open reading frame.
In utero Hh-signaling assays
Generation of Ptc1lacZ, Shh and Smo mutant mice has been
described previously [25,26]. Ptc1lacZ/+mice were kindly pro-
vided by Matthew Scott. Shh+/- and Smo+/- mice were kindly
provided by Andrew McMahon. Agonist solution was pre-
pared in fine suspension in 0.5% methylcellulose/0.2%
Tween 80 at 1.5 mg/ml. Compound was administered by
oral gavage to pregnant mice once a day for two days at
100 l per 10 g body weight. Embryos were collected 24
hours later. Whole-mount in situ hybridization with Ptc1
probe and X-gal staining for whole-mount -galactosidase
detection were performed as described [26]. For histology,
embryos stained with X-gal were post-fixed in 4%
paraformaldehyde, wax-embedded, and 20 m sections
were prepared.
Primary cerebellar cultures
Cerebellar neurons were dissected out of postnatal (one
week) rat brains, and placed into primary cell culture.
Briefly, cells were placed in 96-well plates at a density of
approximately 150,000 cells per well in basal medium of
Eagle (Gibco; Carlsbad, USA) supplemented with 26 mM
KCl, 2 mM glutamine and 10% calf serum. Treatment
agents were added once, on the first day of culture (0 DIV).
Cells were left in culture until 2 DIV, when [3H]-thymidine
was added for 5 hours. Cells were then lysed, and the
incorporation of [3H]-thymidine was determined by scintil-
lation counting.
Neural plate explant assay
Intermediate regions of the open neural tube (i-explants)
were dissected from stage 10-11 chick embryos and embed-
ded in collagen gel [23]. Explants were cultured in Ham-F12
supplemented with 3 g/l D-glucose, Mito Serum Extender
(Collaborative Research; Bedford, USA), penicillin/strepto-
mycin (Gibco), 2 mM L-glutamine (Gibco) and Hh-Ag 1.3
(0.1, 1, 10, 20, 200 and 1000 nM prepared as 1000X stocks
in DMSO; n = 6 explants). As a control, some explants were
cultured with vehicle alone or with octylated Hh-N recom-
binant protein. Cultures were fixed after 22 hours, stained
with mouse monoclonal antibodies against Pax7, MNR2 or
rabbit polyclonal antibodies against Nkx2.2 and the
number of immunoreactive cells per explant counted.
Whole cell/immunocomplex binding assay 
Cultured cells - 70% confluent 293T cells in 6-well plates -
were either left untransfected or transfected using Fugene6
with a pCDNA3.1 construct containing HA-tagged Smo or
v5-epitope tagged 2AR (Invitrogen; Carlsbad, USA). After
48 hours cells were switched from 10% fetal bovine serum
containing DME media to 0.5% FBS containing media sup-
plemented with either 5 nM [3H]-Hh-Ag 1.5 alone or 5 nM
[3H]-agonist plus 5 M of various competitors (see Results).
After 2 hours of incubation at 37°C, cells were washed one
time with PBS and subsequently lysed in 0.5 ml of
lysis/wash buffer containing 1% NP40 in Tris-buffered
saline plus an EDTA-free protease inhibitor cocktail (Roche;
Indianapolis, USA) for 20 minutes at 4°C. Cell extracts were
spun at 14,000 rpm in a microcentrifuge and supernatants
were incubated for 40-60 minutes with either anti-HA beads
(Roche) or anti-v5 antibody (Invitrogen) and Protein A
beads (Pierce; Rockford, USA) to form immunocomplexes.
Immunobeads were then spun down and washed three
times with 0.5 ml lysis/wash buffer per wash. The washed
pellets were then resuspended in SDS sample buffer and
combined with scintillation fluid. Counts per minute (cpm)
for each sample were then determined in a scintillation
counter (Packard topcount).
Membrane binding assays 
Membranes were prepared as follows. Briefly, approxi-
mately 108 cells were transfected with pcDNA 3.1 constructs
(Invitrogen) bearing either murine Smo (wild-type or
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cDNAs using Fugene 6 (Roche). After 48 hours cells were
harvested by scraping in PBS, centrifuged at 1,000 x g for
10 minutes, and gently resuspended in around 10 ml of a
50 mM Tris pH 7.5, 250 mM sucrose buffer containing an
EDTA-free protease inhibitor cocktail (Roche). This cell sus-
pension was then placed in a nitrogen cavitation device
(Parr Instrument Co, Moline, USA) and exposed to nitrogen
gas (230 psi) for 10 minutes. Lysed cells were released from
the device and centrifuged at 20,000 rpm in an SS34 rotor
for 20 minutes at 4°C. Supernatants were discarded and the
pellets were resuspended in 10% sucrose, 50 mM Tris pH
7.5, 5 mM MgCl, 1 mM EDTA solution using three
10-second pulses with a Polytron (Brinkman; Westbury,
USA) at a power setting of 12. Using these membranes, fil-
tration binding assays were performed according to previ-
ously described protocols [28]. To reduce nonspecific
binding, 96-well filtration plates (fiberglass FB filters; Milli-
pore, Bedford, USA) were pre-coated as suggested by the
manufacturer with 0.5% polyethyleneimine + 0.1% BSA
and then washed four times with 0.1% BSA. 
For association and dissociation studies, membranes
(1.5 g total protein) were incubated in polypropylene
tubes with 2 nM [3H]-Hh-Ag 1.5 in the presence or absence
of 2 M competitor in binding buffer (50 mM Tris pH 7.5,
5 mM MgCl, 1 mM EDTA, 0.1 % bovine serum albumin)
plus EDTA-free protease inhibitor cocktail (Roche) in a
final volume of 250 l for 1-26 hours at 37°C. For satura-
tion and competition binding analysis, membranes (1.5 g
total protein) were incubated on the plates with various
concentrations of the [3H]-Hh-Ag 1.5 (plus and minus
competitors) in binding buffer plus EDTA-free protease
inhibitor cocktail (Roche) at a final volume of 1 ml for
approximately 45 hours at 37°C to allow binding to reach
apparent equilibrium. Binding reaction mixtures (0.2 ml
for association/dissociation studies and 0.75 ml in satura-
tion and competition experiments) were then transferred to
the pre-coated 96-well filtration plates (Millipore fiberglass
FB filters), filtered and washed over a vacuum manifold
with six 300 l per well washes of binding buffer supple-
mented with 2% hydoxypropyl cyclodextrin (HPCD;
Sigma; ST Louis, USA) + 0.1% BSA to decrease non-specific
binding. Identical results were obtained if incubations were
done in borosilicate glass or siliconized plastic tubes.
Centrifugation assays were also performed that replicate the
filtration assay results (data not shown). Additionally, these
experiments showed that the extent of ligand depletion was
less than 10% in these studies. Binding-kinetics experi-
ments were performed similarly to the saturation and com-
petition studies. All binding data were evaluated using a
nonlinear regression analysis program (Prism; GraphPad;
San Diego, USA). Ki values were calculated using the
Cheng-Prusoff correction equation [28], where Ki  =
IC50/1+[L]/Kd, and Kd for Hh-Ag 1.5 was determined to be
0.37 nM by the saturation analysis.
Note added in proof
Related results demonstrating the action of cyclopamine on
Smo have been reported by Beachy and colleagues [51,52]. 
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